# **27 FEBRUARY 2024**

#### EQUITY RESEARCH - COMPANY REPORT

# MEGA LIFESCIENCES

THAILAND / COMMERCE

# 4Q23 profit beats with record sales

- MEGA had a very strong core profit of THB621m in 4Q23 (+18.2% q-q, +20.4% y-y), thanks to an all-time revenue high.
- We believe MEGA can grow its profit consistently at 5% CAGR in 2024-26.
- Maintain our BUY rating with TP of THB56.

#### 4Q23 profit beats with all-time revenue high

MEGA reported a net profit of THB473m in 4Q23 (-12% q-q, +18% y-y). Excluding a hefty forex loss and other extra items, the firm had a very strong core profit of THB621m (+18.2% q-q, +20.4% y-y), the second-best quarter in at least ten years, beating our estimate by 8% and Bloomberg's consensus by 16%. This was attributable to the record revenue of THB4.2b (+9.3% q-q, +7.0% y-y), driven by both the Mega We Care brand and the distribution business. The blended gross margin was stable q-q at 45.8% in 4Q23. SG&A expenses were well-controlled. Interest expenses declined after the company paid down its debt. Its fiscal status remains healthy with net D/E at 0.3x and IBD/E at 0.01x.

#### Overall performance in 2023 was flat from high base in 2022

The full-year 2023 core profit was another story. The overall revenues were flat for both the branded and distribution units. 2022 was a high base for its branded business, while the company lost one of its distribution business clients in Myanmar since 1Q23. The 2% y-y increase in core profit was a result of the slightly improved gross margin and decreased SG&A expenses. MEGA declared a dividend payment of THB0.80 apiece, representing a payout ratio of 70%; much higher than its policy of at least 25% of net profit to compensate for its low profit growth.

#### Maintain our profit projections in 2024-26

In 2023, MEGA reported a huge forex loss of THB707m, c70% of which was from the depreciation of the Nigerian naira. Currently, the naira has plunged almost 80% further since the beginning of 2024, indicating an additional forex loss in 1Q24, although some of it will be unrealized. We like MEGA for its strong brand, diversified markets and healthy finances. We believe MEGA can grow its profit consistently at 5% CAGR in 2024-26 with an improved net profit margin to 15.1-15.3%; higher than 10.2-11.8% during the pre-Covid period.

#### Maintain our BUY rating

MEGA shares are good for long-term investment due to its resilient business, in our view. We retain our BUY rating for MEGA with the same TP of THB56 (8.2% WACC, 3.5% LTG). This implies 20x 2024E P/E, equal to its five-year average.



#### Jitra Amornthum Fundamental Investment Analyst on Securities; License no. 014530 jitra.a@fssia.com, +66 2646 9966



# BU

UNCHANGED

TARGET PRICE	THB56.00
CLOSE	THB41.75
UP/DOWNSIDE	+34.1%
PRIOR TP	THB56.00
CHANGE IN TP	UNCHANGED
TP vs CONSENSUS	+11.5%

### **KEY STOCK DATA**

**MEGA TB** 

YE Dec (THB m)	2023	2024E	2025E	2026E
Revenue	15,681	16,139	16,927	17,736
Net profit	1,993	2,444	2,598	2,715
EPS (THB)	2.29	2.80	2.98	3.11
vs Consensus (%)	-	5.7	6.7	2.6
EBITDA	3,285	3,201	3,389	3,535
Recurring net profit	2,327	2,444	2,598	2,715
Core EPS (THB)	2.67	2.80	2.98	3.11
Chg. In EPS est. (%)	nm	0.1	0.1	nm
EPS growth (%)	(11.1)	22.7	6.3	4.5
Core P/E (x)	15.6	14.9	14.0	13.4
Dividend yield (%)	3.8	3.7	3.9	4.1
EV/EBITDA (x)	10.3	10.6	9.9	9.5
Price/book (x)	3.9	3.7	3.5	3.4
Net debt/Equity (%)	(26.4)	(26.3)	(27.5)	(27.7)
ROE (%)	29.9	25.5	25.7	25.8



Sources: Bloomberg consensus; FSSIA estimates

PREPARED BY FSS INTERNATIONAL INVESTMENT ADVISORY SECURITIES CO LTD (FSSIA). ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES CAN BE FOUND AT THE END OF THIS REPORT

#### Investment thesis

Although MEGA posted a very strong core profit of THB621m in 4Q23, the second-best quarter in at least ten years – beating our estimate by 8% and Bloomberg's consensus by 16% - the full-year core profit showed sluggish growth of only 1.6% y-y, with flat revenue. The high base in 2022 could explain the flat growth in 2023. The lack of panic buying in the midst of the pandemic, the economic slowdown in many countries, and the loss of a client would also be reasons, in our view.

The depreciation of the naira is another key short-term risk. However, we think MEGA shares are good for longterm investment due to its resilient business. We retain our BUY rating for MEGA with the same TP of THB56.

#### **Company profile**

MEGA is a leading manufacturer and distributor of pharmaceutical, nutraceutical products and fast-moving consumer goods (FMCG) in developing countries such as Myanmar, Vietnam and Cambodia. MEGA also develops, manufactures, and sells its nutraceutical products, generic prescription pharmaceutical products, and OTC products under Mega We Care brand through its distribution network and third-party distributors in 36 countries across the world.

www.megawecare.com

#### Catalysts

Key potential catalysts include 1) expedited medicine registrations and listings; 2) widespread medical events such as the Covid-19 pandemic; and 3) the success of new products and new markets.

#### Risks to our call

Downside risks to our DCF-based TP include 1) the delayed registration process in many countries; 2) more intensified competition; 3) failure in introducing new products; and 4) risks associated with doing business in Myanmar.

#### Event calendar

Date	Event
6 March 2024	Ex-dividend date
22 April 2024	Payment date of the dividend
6 March 2024	Ex-meeting date
2 April 2024	Annual general meeting of shareholders


#### Principal activities (revenue, 2023)

- Mega We Care 51.0 %
- Maxxcare 47.2 % ■ OEM - 1.8 % Source: Mega Lifesciences

#### Major shareholders

- Unistretch Co Ltd 49.8 %
- Thai NVDR 8.0 %
- Mr. Vivek Dhawan 5.3 %

Others - 36.9 %



Source: Mega Lifesciences

#### Key assumptions

(unit)	2024E	2025E	2026E
(THB m)	8,502	9,097	9,552
(%)	6.2	7.0	5.0
(%)	64.6	64.6	64.6
(THB m)	7,319	7,502	7,847
(%)	(1.0)	2.5	4.6
(%)	23.8	23.4	23.4
(%)	27.8	27.8	27.9
	(THB m) (%) (%) (THB m) (%) (%)	(THB m)         8,502           (%)         6.2           (%)         64.6           (THB m)         7,319           (%)         (1.0)           (%)         23.8	(THB m)         8,502         9,097           (%)         6.2         7.0           (%)         64.6         64.6           (THB m)         7,319         7,502           (%)         (1.0)         2.5           (%)         23.8         23.4

Source: FSSIA estimates

#### Earnings sensitivity

- For every 5% change in branded revenue, we project MEGA's 2024 net profit to change by 6%, all else being equal.
- For every 5% change in distribution revenue, we project MEGA's 2024 net profit to change by 1%, all else being equal.
- For every 1% change in overall gross margin, we project MEGA's 2024 net profit to change by 6%, all else being equal.

Source: FSSIA estimates




#### Exhibit 1: MEGA – 4Q23/2023 earnings summary


V	4089	4000	2022	2000	1000	01-		0000	0000	Ohan
Year to Dec 31	4Q22 (THB m)	1Q23	2Q23	3Q23	4Q23	Cha		2022	2023	Change
	. ,	(THB m)	(THB m)	(THB m)	(THB m)	(q-q %)	(y-y %)	(THB m)	(THB m)	(y-y %)
Sales	3,884	3,728	3,992	3,803	4,158	9.3	7.0	15,686	15,681	(0.0)
Cost of sales	(2,093)	(2,102)	(2,167)	(2,064)	(2,252)	9.1	7.6	(8,647)	(8,586)	(0.7)
Gross profit	1,791	1,626	1,825	1,739	1,905	9.6	6.4	7,040	7,095	0.8
Operating costs	(1,192)	(1,028)	(1,038)	(1,021)	(1,104)	8.2	(7.3)	(4,359)	(4,191)	(3.8)
Operating profit	600	599	787	718	801	11.6	33.6	11,398	11,286	(1.0)
Operating EBITDA	685	685	877	815	908	11.3	32.5	3,033	3,285	8.3
Other income	17	18	19	27	31	16.3	81.2	80	95	18.2
Interest expense	(9)	(9)	(9)	(8)	(5)	(45.1)	(47.8)	(29)	(31)	8.8
Profit before tax	608	607	797	737	828	12.4	36.1	2,733	2,968	8.6
Тах	(68)	(73)	(40)	(98)	(58)	(40.2)	(14.0)	(355)	(269)	(24.1)
Reported net profit	400	453	531	536	473	(11.7)	18.3	2,242	1,993	(11.1)
Extraordinaries										
- Net loss from new businesses	9	12	7	11	10	nm	nm	52	41	nm
- FX los/(gain)	107	81	151	(38)	138	nm	nm	(3)	325	nm
- Normalising tax expense	0	0	(48)	17	0	nm	nm	0	(31)	nm
Core profit	516	546	641	526	621	18.2	20.4	2,291	2,327	1.6
Reported EPS (THB)	0.46	0.52	0.61	0.61	0.54	(11.7)	18.3	2.57	2.29	(11.1)
Core EPS (THB)	0.59	0.63	0.74	0.60	0.71	18.2	20.4	2.63	2.67	1.6
Key ratios (%)	(%)	(%)	(%)	(%)	(%)	(ppt)	(ppt)	(%)	(%)	(ppt)
Gross margin	46.1	43.6	45.7	45.7	45.8	0.1	(0.3)	44.9	45.2	0.4
Operating margin	15.9	16.5	20.2	19.6	20.0	0.4	4.1	17.6	19.1	1.5
EBITDA margin	17.6	18.4	22.0	21.4	21.8	0.4	4.2	19.3	21.0	1.6
Recurring net margin	13.3	14.6	16.1	13.8	14.9	1.1	1.7	14.6	14.8	0.2
SG&A / Sales	30.7	27.6	26.0	26.8	26.6	(0.3)	(4.1)	27.8	26.7	(1.1)
Revenue breakdown	(THB m)	(THB m)	(THB m)	(THB m)	(THB m)	(q-q %)	(y-y %)	(THB m)	(THB m)	(y-y %)
Branded business	2,062	1,953	2,019	1,907	2,126	11.5	3.1	8,053	8,005	(0.6)
Distribution business	1,752	1,717	1,876	1,825	1,980	8.5	13.0	7,320	7,397	1.1
OEM business	71	59	97	71	53	(25.6)	(26.1)	314	280	(11.0)
Gross margin by BU (%)	(%)	(%)	(%)	(%)	(%)	(ppt)	(ppt)	(%)	(%)	(ppt)
Branded business	65.2	64.6	65.8	65.3	64.3	(1.0)	(0.9)	67.0	65.0	(2.0)
Distribution business	23.5	20.4	24.5	25.9	26.6	0.7	3.1	20.8	24.5	3.7
OEM business	46.2	24.6	37.6	27.9	25.6	(2.3)	(20.6)	38.1	30.2	(7.9)

Sources: MEGA, FSSIA's compilation





#### Exhibit 3: Margins and core profit




Sources: MEGA, FSSIA's compilation

Sources: MEGA, FSSIA's compilation


#### 27 FEBRUARY 2024

#### Exhibit 4: Revenue structure by business unit, yearly




Sources: MEGA, FSSIA estimates

#### **Exhibit 6: Revenue projection**




Sources: MEGA, FSSIA estimates

#### Exhibit 8: One-year rolling forward P/E band




Sources: FSSIA estimates, Bloomberg

#### Exhibit 5: Revenue from branded business by region



Sources: MEGA, FSSIA's compilation

#### Exhibit 7: Margins and core profit



Sources: MEGA, FSSIA estimates

#### Exhibit 9: One-year rolling forward EV/EBITDA band



Sources: FSSIA estimates, Bloomberg

#### 27 FEBRUARY 2024

# **FINANSIA**

## **Financial Statements**

Mega Lifesciences

Profit and Loss (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Revenue	15,686	15,681	16,139	16,927	17,736
Cost of goods sold	(8,647)	(8,586)	(8,816)	(9,206)	(9,640
Gross profit	7,040	7,095	7,323	7,720	8,097
Other operating income	80	95	65	68	71
Operating costs	(4,359)	(4,191)	(4,483)	(4,706)	(4,948
Operating EBITDA	3,033	3,285	3,201	3,389	3,535
Depreciation	(272)	(286)	(297)	(307)	(316
Goodwill amortisation	0	0	0	0	(
Operating EBIT	2,761	2,999	2,904	3,082	3,219
Net financing costs	(29)	(31)	(27)	(25)	(25
Associates	0	0	0	0	(
Recurring non-operating income	2	0	(1)	(1)	(
Non-recurring items	(138)	(707)	0	0	(
Profit before tax	2,596	2,262	2,876	3,056	3,194
Tax	(355)	(269)	(432)	(459)	(479)
Profit after tax	2,242	1,993	2,444	2,598	2,715
Minority interests		-	_,	_,000	<b>_</b> ,, it
Preferred dividends	-	-	-	-	
Other items	_				
Reported net profit	2,242	1,993	2,444	2,598	2,715
Non-recurring items & goodwill (net)	50	335	2,444	2,000	2,710
Recurring net profit	2,291	2,327	2,444	2,598	2,715
Per share (THB)					
Recurring EPS *	2.63	2.67	2.80	2.98	3.11
Reported EPS	2.57	2.29	2.80	2.98	3.11
DPS	1.60	1.60	1.54	1.64	1.7
Diluted shares (used to calculate per share data)	872	872	872	872	872
Growth					
Revenue (%)	11.0	0.0	2.9	4.9	4.8
Operating EBITDA (%)	23.2	8.3	(2.6)	5.9	4.3
Operating EBIT (%)	26.2	8.6	(3.2)	6.1	4.4
Recurring EPS (%)	21.4	1.6	5.0	6.3	4.5
Reported EPS (%)	15.1	(11.1)	22.7	6.3	4.5
Operating performance					
Gross margin inc. depreciation (%)	44.9	45.2	45.4	45.6	45.6
Gross margin exc. depreciation (%)	46.6	47.1	47.2	47.4	47.4
Operating EBITDA margin (%)	19.3	21.0	19.8	20.0	19.9
Operating EBIT margin (%)	17.6	19.1	18.0	18.2	18.1
Net margin (%)	15.2	17.2	15.1	15.3	15.3
Effective tax rate (%)	13.7	11.9	15.0	15.0	15.0
Dividend payout on recurring profit (%)	58.6	51.7	55.0	55.0	55.0
Interest cover (X)	96.2	96.0	106.7	121.0	131.2
Inventory days	172.8	164.6	150.0	150.8	150.6
Debtor days	72.0	80.9	82.9	83.0	82.1
Creditor days	163.5	157.6	138.4	135.7	132.9
Operating ROIC (%)	56.8	58.0	47.6	47.3	47.3
ROIC (%)	37.7	39.8	33.6	34.0	34.4
ROE (%)	28.4	29.9	25.5	25.7	25.8
ROA (%)	17.2	19.0	17.1	17.4	17.6
* Pre-exceptional, pre-goodwill and fully diluted					
Revenue by Division (THB m)	2022	2023	2024E	2025E	20265
Mega We Care	8,053	8,005	8,502	9,097	9,552
Maxxcare	7,320	7,397	7,319	7,502	9,552 7,847

Sources: Mega Lifesciences; FSSIA estimates

## **Financial Statements**

Mega Lifesciences

Mega Lifesciences					
Cash Flow (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Recurring net profit	2,380	2,699	2,444	2,598	2,715
epreciation	272	286	297	307	316
ssociates & minorities	0	0	0	0	(
ther non-cash items	474	671	(47)	(244)	(335
hange in working capital	(989)	(1,023)	(845)	(663)	(723
Cash flow from operations	2,136	2,633	1,850	1,998	1,973
Capex - maintenance	-	-	-	-	
Capex - new investment	(305)	(294)	(330)	(300)	(340
Vet acquisitions & disposals	-	-	-	-	
Other investments (net)	24	44	0	0	(
Cash flow from investing	(281)	(250)	(330)	(300)	(340
Dividends paid	(1,406)	(1,439)	(1,344)	(1,429)	(1,493
Equity finance	0	0	0	0	(
Debt finance	2	(237)	(9)	23	(5
Other financing cash flows	(30)	(32)	(27)	(25)	(25
Cash flow from financing	(1,433)	(1,708)	(1,380)	(1,431)	(1,523
Non-recurring cash flows	-	-	-	-	
Other adjustments	0	0	0	0	(
Net other adjustments	(165)	(751)	0	0	(
Movement in cash	257	(76)	139	267	110
Free cash flow to firm (FCFF)	1,884.18	2,414.24	1,546.77	1,723.07	1,657.35
ree cash flow to equity (FCFE)	1,662.78	1,362.98	1,483.56	1,695.36	1,603.49
er share (THB)					
FCFF per share	2.16	2.77	1.77	1.98	1.90
FCFE per share	1.91	1.56	1.70	1.94	1.84
Recurring cash flow per share	3.58	4.19	3.09	3.05	3.09
Balance Sheet (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
angible fixed assets (gross)	4,062	4,309	4,639	4,939	5,279
ess: Accumulated depreciation	(2,161)	(2,334)	(2,631)	(2,938)	(3,254
Fangible fixed assets (net)	1,901	1,974	2,008	2,001	2,025
ntangible fixed assets (net)	1,329	1,318	1,344	1,353	1,343
.ong-term financial assets	1,529	0	0	0	1,54
nvest. in associates & subsidiaries	223	221	221	221	22
Cash & equivalents	2,789	2,712	2,851	3,118	3,228
A/C receivable	3,382	3,570	3,758	3,942	4,033
nventories	4,109	3,377	3,623	3,733	3,962
Other current assets	310	330	345	333	344
Current assets	10,590	9,990	10,578	11,126	11,567
Other assets	603	611	592	593	594
Fotal assets	14,646	14,115	14,743	15,294	15,750
Common equity	8,777	9,302	9,902	10,351	10,723
Minorities etc.	0	0	0	0	(
Fotal shareholders' equity	8,777	9,302	9,902	10,351	10,723
ong term debt	109	132	125	151	148
Other long-term liabilities	223	244	299	313	328
Long-term liabilities	332	376	424	464	476
A/C payable	3,972	3,197	3,261	3,355	3,433
Short term debt	312	120	118	116	114
Other current liabilities	1,254	1,119	1,039	1,009	1,004
Current liabilities	5,538	4,437	4,417	4,479	4,551
fotal liabilities and shareholders' equity	14,646	14,115	14,743	15,294	15,750
Vet working capital	2,575	2,961	3,428	3,645	3,902
nvested capital	6,632	7,086	7,592	7,813	8,085
Includes convertibles and preferred stock which is beir					
Per share (THB)					
Book value per share	10.07	10.67	11.36	11.87	12.30
angible book value per share	8.54	9.16	9.82	10.32	10.76
Financial strength					
Vet debt/equity (%)	(27.0)	(26.4)	(26.3)	(27.5)	(27.7
let debt/total assets (%)	(16.2)	(17.4)	(17.7)	(18.6)	(18.8
Current ratio (x)	1.9	2.3	2.4	2.5	2.5
CF interest cover (x)	69.5	54.0	67.6	79.4	80.2
/aluation	2022	2023	2024E	2025E	2026
Recurring P/E (x) *	15.9	15.6	14.9	14.0	13.4
Recurring P/E (x) " Recurring P/E @ target price (x) *	21.5	18.1	20.0	18.8	13.4
Reported P/E (x)	16.2	18.3	14.9	14.0	13.4
,	16.2 3.8	3.8	14.9 3.7	14.0 3.9	
Dividend yield (%)	3.8 4.1	3.8 3.9	3.7		4. <sup>2</sup> 3.4
Price/book (x)				3.5	
Price/tangible book (x)	4.9	4.6 10.3	4.3	4.0	3.9
EV/EBITDA (x) **	11.2	10.3	10.6	9.9	9.5
	45.0				
EV/EBITDA @ target price (x) ** EV/invested capital (x)	15.3 5.1	14.1 4.8	14.4 4.5	13.6 4.3	13.0 4.1

Sources: Mega Lifesciences; FSSIA estimates



# **MEGA LIFESCIENCES PCL (MEGA TB)**

**FSSIA ESG rating** 

 $\star \star \star$ 

54.48 /100

#### Exhibit 10: FSSIA ESG score implication

Rating	Score	Implication
****	>79-100	Leading its industry peers in managing the most significant ESG risks which not only better cost efficiency but also lead to higher profitability.
$\star\star\star\star$	>59-79	A mixed track record of managing the most significant ESG risks and opportunities relative to industry peers.
***	>39-59	Relevant ESG materiality matrix has been constructively addressed, well-managed and incorporated into day-to-day operations, in which targets and achievements are evaluated annually.
**	>19-39	Relevant ESG materiality matrix has been identified with key management in charge for progress to be followed up on and to provide intensive disclosure. Most targets are conventional and achievable.
*	1-19	The company has adopted the United Nations Sustainable Development Goals (UN SDGs), established sustainability management guidelines and fully complies with regulations or ESG suggested guidance from related organizations such as the SET and SEC.

Source: FSSIA estimates

#### Exhibit 11: ESG – peer comparison

	FSSIA			Domestic ratings					Global ratings					Bloomberg		
	ESG score	DJSI	SET THSI	THSI	CG score	AGM level	Thai CAC	Morningstar ESG risk	ESG Book	MSCI	Moody's	Refinitiv	S&P Global	ESG score	Disclosure score	
SET100	69.20	5.34	4.40	4.40	4.76	4.65	3.84	Medium	51.76	BBB	20.87	58.72	63.91	3.72	28.17	
Coverage	67.12	5.11	4.15	4.17	4.83	4.71	3.53	Medium	52.04	BB	16.97	56.85	62.09	3.40	31.94	
COM7	61.78		Y	Y	5.00	5.00	Certified	Low	47.75			52.68	21.00	4.40	43.59	
MEGA	54.48		Y	Y	4.00	4.00	Declared	Medium	66.56			58.59	24.00	2.39		
BJC	71.33	Y	Y	Y	4.00	4.00		Medium	55.09	A		65.19	89.00	2.16		
CRC	64.49		Y	Y	5.00	5.00	Certified	Medium		BBB		60.98	73.00	2.90	47.27	

Sources: <u>SETTRADE.com</u>; FSSIA's compilation

#### Exhibit 12: ESG score by Bloomberg

FY ending Dec 31	FY 2020	FY 2021	FY 2022
ESG financial materiality scores - ESG score	-	2.29	_
BESG environmental pillar score	_	1.86	—
BESG social pillar score	—	1.06	_
BESG governance pillar score	—	4.54	_
ESG disclosure score	44.34	53.36	_
Environmental disclosure score	29.84	44.22	—
Social disclosure score	19.44	32.16	_
Governance disclosure score	83.59	83.59	_
Environmental			
Emissions reduction initiatives	Yes	Yes	Yes
Climate change policy	Yes	Yes	No
Climate change opportunities discussed	No	No	No
Risks of climate change discussed	No	No	No
GHG scope 1	—	_	633
GHG scope 2 location-based	—	_	6
GHG Scope 3	—	_	0
Carbon per unit of production	—	_	_
Biodiversity policy	No	No	No
Energy efficiency policy	Yes	Yes	Yes
Total energy consumption	24	24	23
Renewable energy use	1	1	1
Electricity used	12	13	12
Fuel used - natural gas	—	_	914

Sources: Bloomberg; FSSIA's compilation

## Exhibit 13: ESG score by Bloomberg (cont.)

FY ending Dec 31	FY 2020	FY 2021	FY 2022
Fuel used - crude oil/diesel	No	No	No
Waste reduction policy	Yes	Yes	Yes
Hazardous waste	_	—	0
Total waste	1	1	1
Waste recycled	0	0	_
Waste sent to landfills	_	—	_
Environmental supply chain management	Yes	Yes	No
Water policy	No	Yes	Yes
Water consumption	_	_	0
Social			
Human rights policy	Yes	Yes	Yes
Policy against child labor	Yes	Yes	Yes
Quality assurance and recall policy	No	Yes	Yes
Consumer data protection policy	Yes	Yes	Yes
Equal opportunity policy	Yes	Yes	Yes
Gender pay gap breakout	No	No	No
Pct women in workforce	56	56	56
Pct disabled in workforce	_	_	_
Business ethics policy	Yes	Yes	Yes
Anti-bribery ethics policy	Yes	Yes	Yes
Health and safety policy	Yes	Yes	No
Lost time incident rate - employees	0	0	_
Total recordable incident rate - employees	_	_	_
Training policy	Yes	Yes	Yes
Fair remuneration policy	No	No	No
Number of employees – CSR	5,714	6,021	5,767
Employee turnover pct		19	
Total hours spent by firm - employee training	70,551	79,892	70,826
Social supply chain management	Yes	Yes	Yes
Governance			100
Board size	10	10	10
No. of independent directors (ID)	4	4	4
No. of women on board	1	1	1
No. of non-executive directors on board	8	8	8
Company conducts board evaluations	Yes	Yes	Yes
No. of board meetings for the year	6	5	7
Board meeting attendance pct	100	96	94
Board duration (years)	3	30	3
Director share ownership guidelines	No	No	No
Age of the youngest director	32	33	34
	32 80	81	34 82
Age of the oldest director	6	6	6
No. of executives / company managers			
No. of female executives	1	1	1
Executive share ownership guidelines	No	No	No
Size of audit committee	3	3	3
No. of ID on audit committee	3	3	3
Audit committee meetings	4	4	4
Audit meeting attendance %	100	100	100
Size of compensation committee	3	3	3
No. of ID on compensation committee	1	1	1
No. of compensation committee meetings	2	2	2
Compensation meeting attendance %	100	100	100
Size of nomination committee	3	3	3
No. of nomination committee meetings	2	2	3
Nomination meeting attendance %	100	100	100
Sustainability governance			
Verification type	No	No	No

Sources: Bloomberg; FSSIA's compilation

# **FINANSIA**

#### **Disclaimer for ESG scoring**

ESG score	Methodolog	У			Rating						
The Dow Jones Sustainability Indices (DJSI) By S&P Global	process base from the ann Only the top- inclusion.	ed on the com ual S&P Glob -ranked comp	transparent, rules-based panies' Total Sustainabi al Corporate Sustainabil anies within each industr	lity Scores resulting ity Assessment (CSA). y are selected for	<ul> <li>Be a member and invited to the annual S&amp;P Global Corporate Sustainability Assessment (CSA) for DJSI. Companies with an S&amp;P Glo</li> <li>ESG Score of less than 45% of the S&amp;P Global ESG Score of the high scoring company are disqualified. The constituents of the DJSI indices selected from the Eligible Universe.</li> </ul>						
Sustainability Investment List ( <u>THSI</u> ) by The Stock Exchange of Thailand ( <u>SET</u> )	managing bu Candidates r 1) no irregula float of >150 up capital. So 70%; 2) inde wrongdoing r	usiness with tr must pass the ar trading of th shareholders ome key disque pendent direct related to CG	ility in Environmental and ansparency in Governan preemptive criteria, with he board members and e a, and combined holding r ualifying criteria include: tors and free float violati , social & environmental aarnings in red for > 3 yea	two crucial conditions: xecutives; and 2) free must be >15% of paid- 1) CG score of below on; 3) executives' impacts; 4) equity in	<ul> <li>during the assessment year. The scoring will be fairly weighted age nature of the relevant industry and materiality.</li> <li><u>SETTHSI Index</u> is extended from the THSI companies whose 1) is capitalization &gt; THB5b (~USD150b); 2) free float &gt;20%; and 3) lice &gt;0.5% of paid-up capital for at least 9 out of 12 months. The SET Index is a market capitalisation-weighted index, cap 5% quarterly</li> </ul>						
CG Score by Thai Institute of Directors Association (Thai IOD)	annually by t Thailand (SE	he Thai IOD,	h in sustainable develop with support from the St ts are from the perspectiv s.	ock Exchange of	Good (80-89), 3 and not rated fo equitable treatr	3 for Good (70 or scores belo nent of shareh 5%); 4) disclo	ories: 5 for Excel I-79), 2 for Fair (6 w 50. Weightings Iolders (weight 29 sure & transpare	60-69), 1 for P include: 1) th 5% combined	ass (60-69), le rights; 2) and ); 3) the role of		
AGM level By Thai Investors Association (TIA) with support from the SEC	treatment are transparent a out of five the criteria cover date (45%), a <i>circulation of su</i> <i>exercised. The</i> <i>and verifiability</i>	e incorporated and sufficiently e CG compon r AGM proced and after the r ufficient informa second assess r; and 3) openne	which shareholders' rights d into business operation y disclosed. All form imp- ients to be evaluated anr lures before the meeting meeting (10%). (The first a tion for voting; and 2) facilitat es 1) the ease of attending n ess for Q&A. The third involve es, resolutions and voting re-	s and information is ortant elements of two nually. The assessment (45%), at the meeting ssesses 1) advance ting how voting rights can be neetings; 2) transparency as the meeting minutes that	Very Good (90-		four categories: (80-89), and not				
Thai CAC By Thai Private Sector Collective Action Against Corruption (CAC)	establishmer policies. The (Companies de Declaration of Certification, in managers and	nt of key contr Certification i eciding to becon Intent to kick off including risk ass	Checklist include corrupti rols, and the monitoring a is good for three years. e a CAC certified member s i an 18-month deadline to sul essment, in place of policy a abilishment of whistleblowing II stakeholders.)	and developing of tart by submitting a bmit the CAC Checklist for nd control, training of	passed Checkli	st will move fo e members a	ed by a committe or granting certific re twelve highly r chievements.	ation by the (	CAC Council		
<u>Morningstar</u> Sustainalytics	based on an risk is unmar	assessment on aged. Sources	sk rating provides an ove of how much of a compa s to be reviewed include corp her media, NGO reports/web	ny's exposure to ESG	more risk is unr	managed, the	score is the sum higher ESG risk	is scored.			
		mpany feedbac uality & peer rev	k, ESG controversies, issuer iews.	feedback on draft ESG	0-10	Low 10-20	Medium 20-30	High 30-40	Severe 40+		
ESG Book	positioned to the principle helps explain over-weightin	o outperform o of financial m n future risk-ad	sustainable companies the ver the long term. The m ateriality including inform djusted performance. Ma th higher materiality and erly basis.	nethodology considers nation that significantly iteriality is applied by	The total ESG s	score is calcul ateriality-base	ated as a weight d weights. The s dicating better p	ed sum of the core is scaled	features		
<u>MSCI</u>				anagement of financially their exposure to ESG ri					nethodology to		
	AAA AA	8.571-10.00	Leader:	leading its industry in m	nanaging the most si	gnificant ESG ris	sks and opportunitie	es			
	A BBB BB	5.714-7.142 4.286-5.713 2.857-4.285	Average:	a mixed or unexception industry peers	al track record of ma	anaging the mos	t significant ESG ris	sks and opportu	nities relative to		
	B CCC	1.429-2.856 0.000-1.428	Laggard:	lagging its industry base	ed on its high expos	ure and failure to	o manage significan	t ESG risks			
<u>Moody's ESG</u> solutions	believes that	t a company ir	· ·	take into account ESG o to its business model and medium to long term.	,						
Refinitiv ESG rating	based on pul	blicly available	e and auditable data. The	e a company's relative ES e score ranges from 0 to are 0 to 25 = poor; >25 to 50	100 on relative E	SG performar	ice and insufficie	nt degree of t			
lating	The SPD Cla			asuring a company's perf ssification. The score ran			of ESG risks, op	portunities, ar	id impacts		
S&P Global		its peers with									
		its peers witr	score is based on Bloo	ating the company's agg mberg's view of ESG fina the weights are determin	ancial materiality.	The score is a	a weighted gener	alized mean (	power mean)		

Rating regarding the sustainable development of Thai listed companies, both on the SET and MAI, are publicly available on the website of the Securities and Exchange Commission of Thailand (SEC). Currently, ratings available are 1) "CG Score"; 2) "AGM Level"; 3) "Thai CAC"; and 4) THSI. The ratings are updated on an annual basis. FSSIA does not confirm nor certify the accuracy of such ratings. Source: FSSIA's compilation

# **FINANSIA**

#### GENERAL DISCLAIMER

#### ANALYST(S) CERTIFICATION

#### Jitra Amornthum FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

#### History of change in investment rating and/or target price



Jitra Amornthum started covering this stock from 20-Feb-2023

Price and TP are in local currency

Source: FSSIA estimates

Company	Ticker	Price	Rating	Valuation & Risks
Mega Lifesciences	MEGA TB	THB 41.75	BUY	Downside risks to our DCF-based TP include 1) the delayed registration process in many countries; 2) more intensified competition; 3) failure in introducing new products; and 4) risks associated with doing business in Myanmar.

Source: FSSIA estimates

#### **Additional Disclosures**

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 23-Feb-2024 unless otherwise stated.

#### **RECOMMENDATION STRUCTURE**

#### **Stock ratings**

Stock ratings are based on absolute upside or downside, which we define as (target price\* - current price) / current price.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

\* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

#### **Industry Recommendations**

**Overweight.** The analyst expects the fundamental conditions of the sector to be positive over the next 12 months. **Neutral.** The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months. **Underweight.** The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

#### **Country (Strategy) Recommendations**

**Overweight (O).** Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

**Neutral (N).** Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

**Underweight (U).** Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

